Showing results (61-70 of 295) with videos related to
Sort By:
Pageof 30
Cell Cycle (Georgetown, Tex.)|March 17, 2012
The expanding proteome of the molecular chaperone HSP90Rahul S Samant, Paul A Clarke, Paul WorkmanCell Cycle (Georgetown, Tex.)|August 23, 2011
Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agentsMounia Beloueche-Babari, Paul Workman, Martin O LeachProceedings of the National Academy of Sciences of the United States of America|April 25, 2014
E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cellsRahul S Samant, Paul A Clarke, Paul WorkmanDrug Discovery Today|February 2, 2020
From patent to patient: analysing access to innovative cancer drugsEva Sharpe, Richard Hoey, Christina Yap, et al.Cancer Cell|September 6, 2008
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosisMarissa V Powers, Paul A Clarke, Paul WorkmanMolecular Cancer Therapeutics|February 20, 2007
The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discoveryNicola F Smith, Florence I Raynaud, Paul WorkmanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2018
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic TargetJacqueline H L Fok, Somaieh Hedayat, Lei Zhang, et al.Plos One|May 26, 2017
SiGNet: A signaling network data simulator to enable signaling network inferenceElizabeth A Coker, Costas Mitsopoulos, Paul Workman, et al.Methods (San Diego, Calif.)|June 11, 2002
Assays for the identification and evaluation of histone acetyltransferase inhibitorsG Wynne Aherne, Martin G Rowlands, Lindsay Stimson, et al.Pharmacology & Therapeutics|February 9, 2017
Inhibitors of cyclin-dependent kinases as cancer therapeuticsSteven R Whittaker, Aurélie Mallinger, Paul Workman, et al.Pageof 30